With the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the source of novel targets. To advance the already pre-validated selection more quickly, the company is now looking for partners. The response has been strong, say Matthias Evers and Hartmut Juhl in conversation with European Biotechnology Magazine.
See-and-Treat Concept using Radioactive Smart Probes: Professor Rudolf Werner provides an overview of established and future indications in clinical practice, highlighting advances in theranostics and their growing impact on precision oncology.
CM4Cure is focused on substantially improving patient outcomes, improving medical device performance by incorporating drug delivery. Our technology redefines medical device coatings – converting passive barriers into active systems via a unique nanogel able to deliver multiple APIs. Initially focused on iv catheters – >2bn are used globally pa – the platform has potential to reduce infection and thrombosis across a swathe of medical devices
Secarna Pharmaceuticals is redefining the discovery and development of oligonucleotide therapeutics to address hard-to-treat disorders. The Company is planning to raise a Series A to advance its lead oncology asset, SECN-15, into Phase 1/2. Secarna is supported by global partnerships that validate their expertise and accelerate development.
3PBIOVIAN has added an additional 2,000-liter single-use bioreactor for mammalian cell culture, further strengthening its industrial capacity and reinforcing its value proposition as a CDMO partner for the development and manufacturing of recombinant proteins.
Chemspec Europe returned to Cologne between 6-7 May 2026, drawing 4,238 attendees from 60 nations and 454 exhibitors from 28 countries, an increase from last year’s event.
Europe continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.
Artificial intelligence is reshaping biotechnology, diagnostics and drug discovery. At the same time, Europe is competing globally for capital, talent and technological leadership. Bio:cap aims to strengthen this ecosystem by connecting investors, startups, researchers and policymakers in a new international investival in Berlin.
The Basel region is one of the world’s leading life-science clusters. Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure and international collaboration. As the industry continues to grow, the demand for scalable laboratory and office environments within this innovation ecosystem is increasing.
Europe continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.
Andre Dallavalle
CM4Cure. All Rights Reserved.
Secarna
Chemspec Europe
3PBIOVIAN
Messe Berlin GmbH
SONUVO
3PBiovian